IGC Pharma Inc
Research IGC Pharma Inc (IGC) on Bullrun: market cap USD 27.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIGC
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 27.12M
- Financial periodFY2025
- RevenueUSD 1.27M
- Revenue growth-5.5%
- Net income-USD 7.12M
- Free cash flow-USD 4.91M
- Gross margin48.7%
Valuation Snapshot
latest market cap is USD 27.12M.
About IGC Pharma Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease.
Frequently asked questions
What is IGC Pharma Inc's market cap?
IGC Pharma Inc's market capitalization is USD 27.12M.
What does IGC Pharma Inc do?
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia.